@anflan @rezdez I want to respectfully point out this is not an apples to apples comparison. For starters, $PTLA is pushing a drug that is more costly than alternative treatments for the underlying condition. It's not price competitive. There is virtually no competition when $AUPH goes to market, not even close. Lupus Foundation of America is closely monitoring $AUPH as well.